Lasa Supergenerics Ltd Share Price & Stock Analysis

Lasa Supergenerics Ltd (NSE: LASA, BSE: 540702) is a Ratnagiri, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹21 Cr, it ranks #4,394 by market cap among the 6,197 Indian listed companies on FinBizNet, and #57 of 63 in Pharmaceuticals. At ₹4.22 (as of 16 Nov 2026), the share price is 65.0% below its 52-week high of ₹12.04 and 0.0% above its 52-week low of ₹4.22. The share price is down 63.3% over one year and down 43.9% over three months.

Key Metrics

Current Price₹4.22
Market Cap₹21 Cr
NSE SymbolLASA
BSE Code540702
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E RatioNot meaningful (loss)
Return on Equity-51.14%
Return on Assets-9.82%
52-Week Range₹4.22 – ₹12.04
1-Year Price Change-63.3%
3-Month Price Change-43.9%
Beta (1Y)1.07
Dividend Yield5.92%
HeadquartersRatnagiri, Maharashtra
Websitelasalabs.com

Latest Quarterly Results — Q2 FY27

Revenue₹0 Cr
Net Profit₹-2 Cr
Net Margin-18400.0%
EPS (Basic)₹-0.37
Basisstandalone

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Lasa Supergenerics Ltd Quarterly Revenue and Profit Trend

Lasa Supergenerics Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.7% from ₹3 Cr in Q2 FY26 and down 99.2% from ₹1 Cr in Q1 FY27. It posted a net loss of ₹2 Cr for the quarter, against a net loss of ₹6 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹-0 Cr (Q4 FY26) to ₹39 Cr (Q4 FY25). The company reported a net loss in 7 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹0 Cr−₹2 Cr−18400.0%
Q1 FY27₹1 Cr−₹4 Cr−291.1%
Q4 FY26₹-0 Cr−₹4 Cr—
Q3 FY26₹2 Cr−₹3 Cr−115.9%
Q2 FY26₹3 Cr−₹6 Cr−204.2%
Q1 FY26₹20 Cr−₹21 Cr−105.5%
Q4 FY25₹39 Cr−₹14 Cr−36.5%

Standalone figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 53.65% of Lasa Supergenerics Ltd's shares as of Sept 2026, unchanged from Sept 2025.

Lasa Supergenerics Ltd Insolvency (CIRP) Disclosures

Lasa Supergenerics Ltd made one exchange disclosure in the Corporate Insolvency Resolution Process (CIRP) category, on 4 Dec 2024. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company. The most recent specific filing, dated 4 Dec 2024, reads: "In continuation of our annoucement dated 13.11.2024 , dismissal of insolvency application as withdraw from Financial Creditor , kindly find attached order for the same as uploaded by NCLT."

Taken from the company's own stock exchange filings. FinBizNet does not infer the current status of any proceeding.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.

Products and Services

1. Active Pharmaceutical Ingredients (API)-This segments engages in the research, manufacture, and marketing of animal and human healthcare products.

Business Segments

1. Active Pharmaceutical Ingredients (API)-100%

Lasa Supergenerics Ltd vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Lasa Supergenerics Ltd₹21 Crn/m-51.14%₹0 Cr-63.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd is trading at ₹4.22, with a market capitalisation of ₹21 Cr.

Which sector does Lasa Supergenerics Ltd belong to?

Lasa Supergenerics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd has a return on equity of -51.14%.

What is the stock symbol of Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd is listed on the NSE under the symbol LASA and on the BSE under the scrip code 540702.

How has Lasa Supergenerics Ltd's share price moved over the past year?

Lasa Supergenerics Ltd's share price is down 63.3% over one year and down 43.9% over three months. Its 52-week range is ₹4.22 to ₹12.04.

What were Lasa Supergenerics Ltd's latest quarterly results?

In Q2 FY27, Lasa Supergenerics Ltd reported revenue of ₹0 Cr and net profit of ₹-2 Cr, with basic EPS of ₹-0.37 (standalone, parsed from the company's exchange filing).

How have Lasa Supergenerics Ltd's revenue and profit changed over the past year?

Lasa Supergenerics Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.7% from ₹3 Cr in Q2 FY26 and down 99.2% from ₹1 Cr in Q1 FY27.

What is the promoter holding in Lasa Supergenerics Ltd?

Promoters held 53.65% of Lasa Supergenerics Ltd's shares as of Sept 2026, unchanged from Sept 2025.

Has Lasa Supergenerics Ltd made any insolvency (CIRP) disclosures?

Lasa Supergenerics Ltd made one exchange disclosure in the Corporate Insolvency Resolution Process (CIRP) category, on 4 Dec 2024. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company. The most recent specific filing, dated 4 Dec 2024, reads: "In continuation of our annoucement dated 13.11.2024 , dismissal of insolvency application as withdraw from Financial Creditor , kindly find attached order for the same as uploaded by NCLT."

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.